Hot Products
Hot products from BioCrick which is a professional high-purity natural products manufacturer are well known to scientists around the world because of their high purity and stability. Each product is a chemical compound or substance produced by a living organism—that is, found in nature. In the broadest sense, natural products include any substance produced by life.Natural products remain the best sources of drugs and drug leads, and this remains true today despite the fact that many pharmaceutical companies have deemphasized natural products research in favor of HTP screening of combinatorial libraries during the past 2 decades. From 1940s to date, 131 (74.8%) out of 175 small molecule anticancer drugs are natural product-based/inspired, with 85 (48.6%) being either natural products or derived therefrom. From 1981 to date, 79 (80%) out of 99 small molecule anticancer drugs are natural product-based/inspired, with 53 (53%) being either natural products or derived therefrom. Among the 20 approved small molecule New Chemical Entities (NCEs) in 2010, a half of them are natural products.
Hot products from the professional high-purity natural products manufacturer
| Cat.No. | Product Name |
|---|---|
| BCC7445 | L-364,373 |
| Activator of KV7.1 (KCNQ1) channels. Activates the cardiac IKs current that decreases action potential duration (APD) in cardiac myocytes. | |
| BCC7448 | BMS 191011 |
| Potent BKCa channel opener (large-conductance Ca2+-activated potassium channel, KCa1.1). Neuroprotectant in two distinct animal models of stroke (MCAO in the SHR rat and a normotensive model of focal stroke). | |
| BCC7453 | Pentylenetetrazole |
| CNS stimulant that induces kindling in vivo. Causes alterations in excitatory and inhibitory neurotransmitter systems. | |
| BCC7455 | YM 90K hydrochloride |
| Selective AMPA receptor antagonist (Ki values are 84, 2200 and > 37000 nM for AMPA, kainate and NMDA receptors respectively). Neuroprotective; delays neuronal death in a global ischemia model and cerebral infarction in a focal ischemia model following postischemic administration. | |
| BCC7459 | PSB 0474 |
| Potent and selective P2Y6 receptor agonist (EC50 values are 70, > 1000 and > 10000 nM for P2Y6, P2Y2 and P2Y4 receptors respectively). Induces contractions of rat isolated intrapulmonary arteries in vitro. | |
| BCC7460 | RWJ 21757 |
| Toll-like receptor 7 (TLR7) agonist; induces immune cell activation and increases cytokine production. Displays antitumor and antiviral activity in various animal models. | |
| BCC7461 | Zoniporide dihydrochloride |
| Sodium-hydrogen exchanger isoform 1 (NHE1) inhibitor that displays selectivity over other NHE isoforms (Ki values are 14, 2200 and 220000 nM for human NHE1, human NHE2 and rat NHE3 respectively). Inhibits NHE1 dependent 22Na+ uptake in vitro (IC50 = 14 nM) and provides cardioprotection from myocardial ischemic injury in vivo (EC50 = 0.25 nM). Also inhibits MMP2/9 activity and invasion in breast cancer cells. | |
| BCC7462 | ACET |
| Potent and selective GluK1 (formerly GluR5) containing kainate receptor antagonist (IC50 = 7 nM) that displays selectivity over GluK2 (formerly GluR6) containing kainate, NMDA, AMPA and group I mGlu receptors. Reversibly blocks induction of NMDA receptor-independent long term potentiation (LTP) in vitro at nanomolar concentrations. | |
